MedTrace Logo

Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Patients With Type 1 Diabetes

NCT00703599 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-07-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether intravenous administration of autologous adipose stem cells is safe and beneficial in patients with type 1 diabetes.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

PROCEDURE

Autologous Adipose-derived Stem cells

Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.

Sponsors & Collaborators

  • Adistem Ltd

    lead INDUSTRY

Principal Investigators

  • Emeritta A Barrenechea, MD · Veterens Memorial Medical Centre, Philippines

  • Florencio Q Lucero, MD · University of Philippines, College of Medicine

  • Letitia Lucero-Palma, MD · Far Eastern University-NRMF Hospital, Quezon City, Philippines

  • Bill Paspaliaris, PhD · Adistem Ltd, Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-11-30
Completion
2009-12-31

Countries

  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00703599 on ClinicalTrials.gov